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Abstract
Diabetes has become a public health crisis. With the incidence of obesity rising in the United States, the number of diabetics will
grow considerably. Of greatest concern is the impact this trend will have on cardiovascular disease. Diabetics demonstrate acceler-
ated coronary atherosclerosis, and the prognosis is worse following cardiac events. Moreover, our interventions have achieved
uneven success in treating this subset of patients. This paper will review the metabolic abnormalities that promote atherosclerosis in
diabetics and the current methods for treating and preventing the development of coronary artery disease in diabetics, principally
through a combination of medications and revascularization.
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Introduction
DIABETES HAS BECOME a public health crisis.
With the incidence of obesity rising in the United
States, the prevalence of diabetes is expected to
grow from 16 million cases to an estimated 22
million by 2025 (1). The effect of this on cardio-
vascular disease is unquestionable. Diabetic men
have a threefold increase in the risk of cardiac
disease compared to nondiabetics. And studies
have shown that diabetics with no prior myocar-
dial infarction have a risk of infarction similar to
that of nondiabetics with a history of myocardial
events (2); see Fig. 1 (3). Diabetic women are es-
pecially vulnerable and appear to lose their pre-
menopausal protection from coronary artery dis-
ease (4). Unfortunately, our measures against
cardiovascular disease have seen a smaller de-
cline in cardiovascular mortality for diabetics
compared to the general population.
Since more than 90% of diabetics are type
2, our prevention strategies begin by targeting
the constellation of metabolic derangements
seen in these patients, collectively called “syn-
drome X” or the cardiovascular dysmetabolic
syndrome (5). These include insulin resistance
(from impaired glucose tolerance to hyper-
glycemia), dyslipidemia, hypercoagulability,
and hypertension. Multiple drugs are utilized to
slow the progression of atherogenesis in these
patients. And the onset of symptomatic coro-
nary artery disease heralds the need for revas-
cularization, often with varying results in dia-
betics. The following discussion will review the
metabolic predisposition to atherosclerosis in
diabetics and highlight the pharmacologic and
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Fig. 1. Event rates, RR and CI for cardiovascular death (CVD)
in diabetics and nondiabetics (n=8,013) with and without a
history of CVD after hospitalization for coronary syndromes.
RR = relative risk, CI = 95% confidence interval (3).
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revascularization options that comprise their
medical management.
Hyperglycemia
Hyperglycemia as a cause of vascular dis-
ease has been observed experimentally in ani-
mal models, and clinically through the benefits
of tight glucose regulation. The Diabetes Con-
trol and Complications Trial (DCCT) demon-
strated that aggressive glycemic control in type
I diabetics reduces the risk of microvascular
complications including retinopathy, microal-
buminuria, and clinical neuropathy by 76%,
39%, and 60%, respectively (6). A similar trend
was seen in type 2 diabetics in the United King-
dom Prospective Diabetes Study (UKPDS),
where fasting glucose levels of less than 108
mg/dL resulted in a 25% reduction in the risk of
microvascular disease over 10 years (7).
The link between hyperglycemia and
macrovascular disease, which was not clearly
demonstrated in these large trials, has been
shown in smaller studies. The San Antonio
Heart Study showed a proportional increase in
cardiovascular-related deaths with higher fast-
ing blood glucose levels in type 2 diabetics (8).
A similar result appeared for type I diabetics in
the Wisconsin Epidemiologic Study of Diabetic
Retinopathy, where patients were followed for
10 years and demonstrated an 18% increase in
cardiovascular mortality and a 1% increase in
glycosylated hemoglobin (9).
Insulin Resistance
For type 2 diabetics the presence of insulin
resistance and hyperinsulinemia accelerates the
development of atherosclerosis. One study
showed hyperinsulinemia as an independent
risk factor when adjusted for lipid profile, hy-
pertension and family history (10). Studies of
multiple ethnic groups have shown increased
carotid intima-medial thickness (a reliable
marker for coronary disease) in subjects with
insulin resistance (11). Furthermore, impaired
glucose tolerance (IGT), even without frank hy-
perglycemia, can increase the risk of heart dis-
ease (12). Since insulin resistance can precede
clinically diagnosed diabetes by 10 – 15 years,
this extensive period of atherogenic exposure
may account for the higher rates of cardiovas-
cular disease in type 2 diabetics.
There are multiple pharmacologic options
for these patients, each utilizing a different
mechanism for lowering blood glucose levels.
The major classes of drugs include: thiazo-
lidinediones (troglitazone, rosiglitazone, piogli-
tazone); biguanides (metformin); and insulin
secretagogues (sulfonylureas, repaglinide).
The thiazolidinediones act in the nucleus of
muscle and adipose tissue to increase transcrip-
tion and translation of surface glucose trans-
porters. This augments insulin-mediated uptake of
glucose, reducing glycosylated hemoglobin levels
by as much as 1.5% (13). By sensitizing the action
of circulating insulin, daily insulin requirements
are reduced, sometimes by 50%, and the risk of
hypoglycemia is lowered compared to other dia-
betic agents. Although these agents increase low-
density lipoprotein (LDL) levels, they reduce
triglycerides and small, dense LDLs (which are
atherogenic), while raising high-density protein
(HDL) levels and minimizing harmful oxidative
changes to normal LDL (14). Disadvantages of
this therapy include hepatotoxicity, weight gain,
fluid retention and slow onset of action, with low-
est glucose levels achieved 6 – 8 weeks after initi-
ating therapy. All three thiazolidinediones are felt
to be safe and equally efficacious as monotherapy
or in conjunction with insulin (15), metformin
(16), or sulfonylureas (17). Nevertheless,
monotherapy with troglitazone is discouraged be-
cause of hepatotoxicity, which is lower with
rosiglitazone and pioglitazone. The effect of thia-
zolidinediones in preventing coronary artery dis-
ease requires further study, but positive data has
emerged from a randomized, controlled trial
showing troglitazone reducing neointimal hyper-
plasia (a cause of stent restenosis) in diabetics re-
ceiving coronary stents (Table 1) (18).
Sulfonylureas target pancreatic beta cells,
where they block potassium-adenosine triphos-
phate (K-ATP) channels, thereby increasing in-
tracellular calcium and promoting the release of
insulin. This method controls blood sugar but is
worrisome, since it may induce hypoglycemia in
patients. The UKPDS data revealed a 16% re-
duction in myocardial infarctions (MI) for pa-
tients treated with sulfonylurea or insulin, with
no significant difference between the two agents.
There was a 1 – 1.4% yearly rate of severe hypo-
glycemia in the sulfonylurea-treated group (7).
An additional concern emerges from trials
showing an increased risk of MI and death in the
setting of ischemia for patients taking sulfonyl-
ureas. The blocking of cardiac K-ATP channels
is purported to reduce ischemic preconditioning,
a phenomenon in which the heart becomes toler-
ant to further ischemia or reperfusion after an
initial ischemic insult (19). This claim has been
supported in a study showing increased in-hospi-
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tal mortality of diabetics taking sulfonylureas
and receiving percutaneous transluminal coro-
nary angioplasty (PTCA) for acute MI. However,
long-term mortality, risk of MI and need for
coronary artery bypass graft (CABG) were no
different between the two groups (20). This po-
tential harm has also been disputed by the
UKPDS data, which demonstrated no difference
in myocardial events between the sulfonylurea
group and the insulin group. Further study is
necessary to resolve this issue.
Metformin promotes glucose control in two
ways: (a) by decreasing hepatic glucose release
through an inhibition of gluconeogenesis, and
(b) by increasing the sensitivity of peripheral
tissue to insulin (21). In the UKPDS trial, met-
formin demonstrated significant reductions in
all diabetes-related endpoints for obese diabet-
ics. This finding, combined with its effect on
promoting weight loss and reduced risk of hy-
poglycemia, supports metformin as a first line
therapy, particularly for obese patients (22).
Metformin also improves lipid and coagulation
profiles. Decreased levels of LDL, triglycerides
and plasminogen activator inhibitor-1 (PAI-1),
which have been observed in treatment groups,
may provide additional protection from cardio-
vascular disease (23). Lactic acidosis is a side
effect, although rare, and limits the use of met-
formin in patients with chronic renal insuffi-
ciency, congestive heart failure, or hypoxia (24).
Hyperlipidemia
Dyslipidemia in diabetics involves elevated
triglyceride levels and decreased HDL levels.
While LDL is typically normal in type 2 diabet-
ics, it is often small and dense, with impaired
antioxidant defenses. Glycosylation of protein
and phospholipid components further increases
its vulnerability to oxidative changes, a process
that promotes atherogenesis (25).
Elevations of very low-density lipoproteins
(VLDLs) are also seen. These VLDLs are the re-
sult of: (a) increased free fatty acid return to the
liver due to obesity, which increases available
quantities of fatty acids, and (b) insulin resistance,
which decreases catabolism of fatty acids by pe-
ripheral tissue. In the liver, these fatty acids are
used to generate triglyceride-rich VLDLs of vary-
ing sizes, which are atherogenic. Lipoprotein li-
pase, an enzyme responsible for eliminating
VLDL within the circulation, is less active in dia-
betics, further contributing to VLDL increase (26).
Elevated VLDL is also involved in the
pathogenesis of decreased HDL levels. With
their triglyceride-rich cores, VLDLs promote
the exchange of triglycerides for key choles-
terol components in HDL, resulting in a triglyc-
eride-laden HDL that is easily degraded by en-
zymes (27). Moreover, studies have shown that
the circulating HDL in diabetic patients may be
less effective in preventing coronary artery dis-
ease (CAD), by allowing the oxidation of LDL
to occur unchecked (28). Altogether, these
triglyceride-mediated changes in VLDL and
HDL may account for hypertriglyceridemia as a
risk factor for coronary disease in diabetics, but
not in the general population.
Multiple trials have demonstrated benefits
from treatment with hydroxymethyl glutaryl coen-
zyme A (HMG CoA) reductase inhibitors (simva-
TABLE 1
IVUS* Were Performed on 62 Stented Lesions in 52 Patients with NIDDM to Determine Whether Troglitazone (400 mg)
Reduced Neointimal Tissue Proliferation after Coronary Stent Implantation
IVUS Measurements after Troglitazone Control p value
6 months of treatment (n=29 stents) (n=33 stents)
Stent area (mm2) 7.3±1.8 7.3±2.3 0.7995
Lumen area (mm2) 5.3±1.7 3.7±1.7 0.0002
Intimal area (mm2) 2.0±0.9 3.5±1.8 <0.0001
Intimal index (%) 27.1±11.5 49.0±14.4 <0.0001
Reprinted with permission from J Am Coll Cardiol 2000; 36(5):1529 – 1535, Table 3 (18).
*IVUS = quantitative intravascular ultrasound studies
NIDDM = non-insulin-dependent diabetes mellitus.
Intimal Index =
Averaged Intimal Area 
× 100%
Averaged Stent Area
Reduction in plasma glucose and insulin levels was significantly greater with troglitazone as compared to placebo
(p<0.0001 for both).
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statin, pravastatin) and fibric acid derivatives
(gemfibrozil) as modes of lipid therapy. Subset
analyses from these data show similarities in car-
diovascular risk reduction for diabetics, compared
to nondiabetics (Table 2) (29 – 34). The 4S and
CARE trials yielded significant declines in the
rates of death, nonfatal MI, and revascularization
in diabetics treated with simvastatin and prava-
statin, respectively, against placebo. The latter trial
showed a 25% reduction in cardiac events over 5
years. Gemfibrozil is effective in raising HDL lev-
els and lowering triglycerides, both of which are
effective in limiting the progression of heart dis-
ease. In the Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial (VA-
HIT), a 22% reduction in cardiac deaths and non-
fatal MIs combined was observed among diabetics
treated with gemfibrozil against placebo. LDL lev-
els were normal and unaffected during the treat-
ment period (35). Similar benefits were seen years
earlier in the Helsinki Heart Trial, indicating the
importance of treating low HDL, even with normal
LDL, as is seen in many type 2 diabetics (36).
Hypertension
The presence of hypertension in diabetic pa-
tients significantly increases their risk of micro-
and macrovascular complications, including
retinopathy, nephropathy and cardiac disease.
Several studies have demonstrated the benefits of
blood pressure control in reducing these morbid
sequelae. In the UKPDS trial, a target blood pres-
sure of <150/85 resulted in a 24% risk reduction
in diabetes-related endpoints (p=0.0046), includ-
ing a 34% risk reduction (p=0.019) in combined
macrovascular disease (MI, sudden death, stroke,
and peripheral vascular disease) and a 37% re-
duction in risk of microvascular disease
(p=0.0092). The 21% reduction in MI was not
statistically significant, but the risk of heart fail-
ure decreased by 56% (p=0.0043) (37).
In the UKPDS trial, these results were similar
whether blood pressure was controlled with a
beta-blocker (atenolol) or with an angiotensin-
converting enzyme (ACE)-inhibitor (captopril),
suggesting no advantage between different blood
pressure regimens (38). However, recent data dis-
pute this finding. The Captopril Prevention Pro-
ject (CAPPP) trial demonstrated a statistically
significant decrease in cardiac events, including
MI and cardiovascular mortality, in diabetic pa-
tients treated with captopril vs. beta-blocker and
diuretic therapy (39). Additionally, the Appropri-
ate Blood Pressure Control in Diabetes (ABCD)
trial showed fewer episodes of fatal and nonfatal
MIs in diabetics taking enalapril vs. a calcium
channel blocker (nisoldipine) (40).
For diabetics, ACE-inhibitors may exert
cardiovascular protection beyond their blood
pressure lowering effect. This was seen in the
Heart Outcomes Prevention Evaluation (HOPE)
trial, where 5-year rates of MI, stroke, and car-
diovascular mortality were reduced in diabetics
treated with enalapril compared to placebo (rel-
ative risk reduction=25%, p=0.0004). This ben-
efit was disproportionately larger than the mean
drop in systolic blood pressure (6 mm Hg).
Since many of these patients also did not have
baseline hypertension, enalapril may be cardio-
protective through other mechanisms, possibly
related to angiotensin II blockade. These are
thought to include reduced vasoconstriction and
left ventricular hypertrophy, improved endothe-
lial function, decreased smooth muscle prolifer-
ation, and stabilization of coronary plaques (41).
The concept of further lowering blood pres-
sure, even when patients are “normotensive,”
TABLE 2
A Series of Clinical Trials Demonstrating the Risk Reduction of Major Coronary Events for Patients Treated with HMG-
CoA Reductase Inhibitors (29 – 34)
Study Drug No. of Diabetics Risk Reduction Risk Reduction
(nondiabetics) (diabetics)
Primary Prevention
AFCAPS/TexCAPS lovastatin 239 37% (all patients) 43%
Secondary Prevention
Heart Protection Study simvastatin 5963 27% (all patients) 27% * (p<0.0001)
CARE pravastatin 586 23% 25% (p=0.05)
4S simvastatin 202 32% 55% (p=0.002)
LIPID pravastatin 782 25% 19%
4S-extended simvastatin 483 32% 42% (p=0.001)
* A portion had no prior cardiovascular disease, thereby providing data for primary prevention.
Vol. 71 No. 6 CARDIOVASCULAR DISEASE IN DIABETICS—MANGALMURTI 379
appears particularly beneficial in diabetics. The
Hypertension Optimal Treatment (HOT) study
yielded a 50% reduction in major cardiovascu-
lar events in diabetic patients with diastolic
blood pressures of 80 mm Hg or less compared
to pressures of 90 mm Hg or less. A similar im-
provement was seen for strokes, silent MIs, and
cardiovascular mortality (42).
Beta-blocker treatment for diabetics has tra-
ditionally focused on post-MI patients, for whom
mortality benefits have been proven (43). Yet
there are concerns that these agents may be harm-
ful to diabetics by masking hypoglycemic symp-
toms, raising lipid levels and worsening glucose
tolerance. Recent data show no long-term effects
on lipid profiles, although lower HDL levels and
higher triglycerides were seen during the initial
titration period (44). Furthermore, studies of MI
patients treated with beta-blockers show no in-
crease in complications related to their diabetes
(45). Meanwhile, the benefits of treatment have
become increasingly apparent. The Benzafibrate
Infarction Prevention (BIP) study showed a 42%
reduction in cardiac mortality in type 2 diabetics
treated with beta-blockers. These patients had
chronic CAD and remote histories of MI, sug-
gesting a broader role for therapy beyond the im-
mediate post-MI period (46).
Antiplatelet Drugs
Elevated levels of thromboxane, fibrinogen,
PAI-1 and several coagulation factors suggest a
link between diabetes and a procoagulant state
(47). Antiplatelet therapy involves multiple
pharmacologic agents, each with its own mech-
anism for platelet inhibition. The three major
drugs used in cardiovascular disease include as-
pirin, clopidogrel and intravenous glycoprotein
(GP) IIb/IIIa inhibitors.
Data from the BIP study suggest that diabet-
ics derive even greater cardiovascular benefits
from aspirin than do nondiabetics (48). One rea-
son may have to do with elevated levels of
thromboxane, a platelet aggregant, observed in
diabetics and inhibited by aspirin therapy. For
this reason, low-dose aspirin therapy is recom-
mended as a primary prevention in diabetics with
one other risk factor for coronary disease (49).
The role of additional antiplatelet agents is
important for diabetics, since they experience in-
creased mortality from acute coronary syndromes
(ACS) (50). Clopidogrel (Plavix) blocks adeno-
sine diphosphate-mediated platelet activation and
subsequent aggregation. Its efficacy in acute
coronary syndromes was demonstrated in the
Clopidogrel in Unstable angina to prevent Recur-
rent Events (CURE) trial, in which patients
treated with aspirin plus clopidogrel, compared to
aspirin alone, had significant risk reductions in
cardiovascular mortality, nonfatal MI and stroke
combined, as well as refractory ischemia (51). An
extension of this effect was seen in patients re-
ceiving long-term clopidogrel therapy after per-
cutaneous coronary intervention (PCI) (Fig. 2)
(52). Necessity for target vessel revascularization
within 30 days of PCI was also significantly less
in the treated group (53). In both studies, diabetic
subgroups also demonstrated these benefits.
Intravenous GPIIb/IIIa inhibitors target the
final step in platelet aggregation, where fibrino-
gen binds glycoprotein IIb/IIIa and promotes
cross-linking of platelet molecules (53). The
PRISM-PLUS study showed decreased mortal-
ity, myocardial infarction and refractory is-
chemia after 7 days in diabetics with unstable
angina treated with a GPIIb/IIIa plus heparin
vs. heparin alone (54). A meta-analysis of six
GPIIb/IIIa trials, including PRISM-PLUS,
demonstrated a 30-day mortality reduction from
6.2% to 4.6% (p=0.007) in diabetics with ACS
and an even greater benefit in diabetics under-
going PCI. No survival difference was seen be-
tween therapies for nondiabetics (55).
Myocardial Infarction
Management of acute MI in diabetics is of
special concern, since they have a higher inci-
dence and a higher mortality from these events.
Fig. 2. Long-term clopidogrel therapy in 2,658 patients
with non-ST elevation acute coronary syndrome undergo-
ing percutaneous coronary intervention showed a 31% risk
reduction in cardiovascular death and myocardial infarc-
tion (p=0.002). ASA = aspirin. Reprinted with permission
from Elsevier, Lancet 2001; 358:527 – 533 (52).
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Thrombolytic therapy has the same, if not
greater short-term benefits for diabetics vs.
nondiabetics in spite of their elevated coagula-
tion factors. Multiple angiographic studies have
demonstrated similar patency rates between
these two groups 90 minutes after thrombolysis
(56). And an analysis of all thrombolytic trials
demonstrated a non-significant, but increased
35-day survival rate for diabetics (57).
Novel approaches for improving survival
after myocardial infarction include aggressive
glucose control with insulin during the peri-
infarct period. The DIGAMI trial randomized di-
abetic patients with acute MIs to insulin infusion
for 24 hours upon hospitalization, followed by
three months of subcutaneous insulin therapy.
This was compared to standard glucose control
therapy. A 30% and 28% reduction in mortality
was seen in the insulin infusion group after 1 and
3.4 years of follow-up, respectively (58).
Revascularization
Coronary revascularization, through angio-
plasty or CABG, is critical to any long-term
survival strategy for patients with cardiovascu-
lar disease. Diabetes poses a unique challenge
by accelerating the development of multi-vessel
atherosclerosis before and after these proce-
dures (59). The effect this has on the manage-
ment of diabetics is seen in results from the By-
pass Angioplasty Revascularization Investiga-
tion (BARI) trial. This study demonstrated that
5-year survival rates were significantly im-
proved for diabetics with multi-vessel disease
treated with CABG (survival rate 80.6%) com-
pared to balloon angioplasty (65.5% survival,
p=0.003). This difference was not seen in the
nondiabetic subset. The benefits of surgery
could be explained by more widespread coro-
nary disease in diabetics, and higher rates of
restenosis after PTCA (60). Interestingly, other
trials do not confirm this result. A prospective
nonrandomized study at Duke University found
no difference in 5-year survival between diabet-
ics with multi-vessel disease treated with
CABG compared to PTCA (61). Furthermore,
an examination of outcomes among BARI reg-
istry patients yielded similar 7-year mortality
rates (26%) between CABG and PTCA-treated
diabetics when physicians chose the modality
of revascularization, selecting PACA for 65%
of all patients (62). Regardless of the therapy,
diabetics still demonstrate higher mortality
rates than nondiabetics after PCI, resulting in
large part from higher rates of restenosis.
The problem of restenosis is being ad-
dressed through advances in PCI techniques, in-
cluding antiplatelet administration and coro-
nary stent placement. The EPIC and EPILOG
trials demonstrated a reduction in acute is-
chemic complications after angioplasty with the
administration of a GPIIb/IIIa inhibitor (63).
The latter trial showed a continuation of bene-
fits six months after therapy (64).
Furthermore, placement of coronary stents
during angioplasty significantly lowers resteno-
sis rates in simple lesions for both diabetics and
nondiabetics, as demonstrated by the STRESS
and BENESTENT trials (65). The BENES-
TENT study showed a 22% restenosis rate after
stent insertion compared to 32% for angioplasty
alone (p=0.02), with benefits also seen after 5-
year follow-up (66, 67).
A combination of stent and antiplatelet ther-
apy demonstrates the most significant mortality
benefits. The EPISTENT trial compared out-
comes after 6 months for patients treated with
stent combined with abciximab (GPIIb/IIIa in-
hibitor), abciximab and angioplasty, or stent
placement alone. There was a 50% reduction in
mortality, nonfatal MI and repeat revasculariza-
tion for diabetics receiving stent and abciximab
vs. stent and placebo. Diabetics also showed
lower rates of repeat target vessel revascular-
ization after treatment with stent and abciximab
(8.1%) vs. angioplasty and abciximab (18.4%,
p=0.008) or stent alone (16.6%, p=0.02) (68).
Even with the advent of coronary stents,
CABG appears to be more beneficial in diabet-
ics compared to PCI. In the Arterial Revascu-
larization Therapy Study (ARTS) trial, diabet-
ics receiving CABG surgery had significantly
fewer cardiac events (84.4% event-free sur-
vival) at one year than those treated with multi-
vessel stenting (63.4% event-free survival,
p<0.001). One reason was the greater need for
repeat revascularization procedures in the PCI
group due to stent restenosis. The addition of a
GPIIb/IIIa inhibitor may improve outcomes for
diabetics receiving multi-vessel stenting, but
this requires further study (69).
Preventing stent restenosis is the current
challenge in coronary revascularization.
Restenosis, which is accelerated in diabetics, re-
sults from neointimal hyperplasia secondary to
smooth muscle proliferation. Many oncologic
agents are being studied for their effect on in-
hibiting this process, including paclitaxel, c-
myc, sirolimus, actinomycin-D, tacrolimus and
dexamethasone. For example, sirolimus binds to
its intracellular receptor protein FKBP12 in target
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cells, resulting in elevations of p27kip1, a cyclin-de-
pendent kinase inhibitor. This reduces phosphory-
lation of cell-cycle progression protein Rb
(retinoblastoma protein), thereby inducing cell
cycle arrest and inhibition of vascular smooth
muscle proliferation (53). These drugs, however,
have shown little success when given systemi-
cally, leading to the development of in-situ deliv-
ery systems such as drug-eluting stents. Local ad-
ministration of these drugs allows higher doses to
be given with less concern for the toxic side ef-
fects associated with systemic delivery. Favorable
results have been achieved in clinical trials using
sirolimus-eluting stents for patients with and
without diabetes (Table 3). Results of the RAVEL
trial demonstrated significantly reduced rates of
neointimal hyperplasia in patients treated with
sirolimus-coated stents versus non-coated stents.
This resulted in a reduction of stent restenosis at
six months with no patients showing greater than
50% stent narrowing in the sirolimus group com-
pared to 25% (p<0.001) in the standard group. Di-
abetics in this study experienced similar benefits,
showing 0% restenosis with sirolimus but 41.7%
restenosis without the drug (p=0.002) (70).
The SIRIUS trial randomized 1,058 patients
(279 diabetics) to sirolimus-coated stents vs.
standard stents, and followed clinical endpoints
at 9 months. Diabetics showed statistically sig-
nificant reductions in the rates of restenosis and
repeat revascularization (Table 3) in addition to
decreased MI and death (71). The FREEDOM
Trial will investigate whether drug-eluting
stents can improve outcomes in diabetics with
multi-vessel disease when compared to CABG.
Future Directions
Diabetes poses a unique and pressing chal-
lenge in the management of cardiovascular dis-
ease. The BARI-2D trial will address many unan-
swered questions in this area, including the role of
revascularization in stable, and even asympto-
matic, CAD in diabetics. Patients will be random-
ized to aggressive medical management combined
with revascularization (CABG or PCI) vs. aggres-
sive medical management only. The study will
also examine outcome differences between an in-
sulin-based approach to glycemic control and an
insulin-sensitizing strategy, which targets insulin
resistance (72). In the future, the clinical effects of
new pharmacologic agents, such as the thiazo-
lidinediones, in preventing development and pro-
gression of cardiovascular disease will need to be
addressed. Moreover, the potential negative im-
pact of current pharmacologic agents in diabetics,
such as sulfonylurea in acute myocardial infarc-
tions, requires further study. And with the advent
of drug-eluting stents, many of the same manage-
ment questions and dilemmas addressed in prior
clinical trials with diabetics will be revisited.
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